SLC16A3 and head and neck squamous cell carcinoma: We demonstrated that EGFRHIGH tumor subcluster was distinctly elevated in the pembrolizumab-treated group and exhibited significantly higher level of lactate producing biomarkers including LDHA and SLC16A3 compared to the combination group in both HNSCC and LUSC PDX.